Browsing Tag
Ixo-vec
2 posts
Can Lilly’s milestone-heavy deal for Adverum reshape how Big Pharma acquires gene therapy platforms?
Lilly’s $12.47-per-share buyout of Adverum Biotechnologies puts milestone CVRs at the center of biotech M&A. But can this deal model truly balance risk and reward?
Lilly’s $262m Adverum Biotechnologies buyout marks a major push into ocular gene therapy
Find out how Eli Lilly’s $262 million Adverum Biotechnologies buyout is advancing gene-therapy innovation in vision care!